pipeline-prospector-insert-v1
X

Find Novel Oncology Drugs in Clinical Development in NETHERLANDS

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Vγ9Vδ2 T cells based antibodies,V?9V?2 T cells based antibodies

            Therapeutic Area: Oncology

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: ProBioGen AG

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement January 14, 2020

            Details:

            Under the agreement and using its CHO.RiGHT™ expression platform, ProBioGen will conduct cell line development of a γδ T-cell engaging bispecific antibody format.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Antibody drug conjugate linker

            Therapeutic Area: Oncology

            Highest Development Status: Undisclosed Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Shanghai Miracogen

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement January 07, 2020

            Details:

            Miracogen has been granted non-exclusive rights to Synaffix’s proprietary GlycoConnect™ and HydraSpace™ ADC technologies for use in this second clinical candidate.